What is Montelukast Used For?
Montelukast, sold under the brand name Singulair, is a medication primarily used for the maintenance treatment of asthma, a chronic inflammatory disease of the airways. It is also used for the symptomatic treatment of seasonal allergic rhinitis (hay fever) and perennial allergic rhinitis [1].
How Does Montelukast Work?
Montelukast works by blocking the action of leukotrienes, substances in the body that can cause inflammation and constriction of airways, leading to symptoms of asthma and allergies. By inhibiting the action of leukotrienes, Montelukast helps to relieve symptoms such as wheezing, coughing, and shortness of breath in people with asthma, as well as sneezing, runny nose, and itchy eyes in individuals with allergic rhinitis [2].
Difference Between Montelukast and Other Allergy Treatments
Montelukast differs from other allergy medications in that it is not an antihistamine, whereas antihistamines such as diphenhydramine and loratadine are commonly used to treat allergies. However, Montelukast may be used in conjunction with antihistamines to provide additional relief for allergy symptoms [3].
Why Choose Montelukast for Allergies?
Some users may prefer Montelukast for allergies due to its once-daily dosing schedule, making it easier to adhere to treatment. Additionally, Montelukast has been shown to have a favorable safety profile, making it a viable option for long-term use [4].
When Will the Patent for Montelukast Expire?
According to DrugPatentWatch.com, the patent for montelukast (Singulair) expired in 2007, allowing generic versions of the medication to enter the market [5]. This has led to increased competition and potentially lower prices for consumers seeking generic montelukast.
Sources:
[1] DrugPatentWatch.com. "Singulair (montelukast) Patent and Exclusivity Expiration Dates."
[2] RxList.com. "Singulair (montelukast) Side Effects, Interactions, Uses & More."
[3] Healthline.com. "Montelukast vs Antihistamines: Which is Best for Allergies?"
[4] Pubmed.gov. "Montelukast: a review of its use in the management of asthma and allergic rhinitis."
[5] DrugPatentWatch.com. "Singulair (montelukast) Patent and Exclusivity Expiration Dates."